Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Trine Alma Knudsen; Dennis Lund Hansen; Lukas Frans Ocias; Ole Weis Bjerrum; Mette Brabrand; Daniel El Fassi; Mikael Frederiksen; Lasse Kjær; Thomas Kielsgaard Kristensen; Torben A Kruse; Torben Mourits-Andersen; Peter Møller; Ulrik Malthe Overgaard; Marianne Tang Severinsen; Vibe Skov; Jesper Stentoft; Jørn Starklint; Karin de Stricker; Mads Thomassen; Thomas Stauffer Larsen; Hans Carl Hasselbalch

doi:10.1182/blood-2018-99-111255

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Trine Alma Knudsen, Dennis Lund Hansen, Lukas Frans Ocias, Ole Weis Bjerrum, Mette Brabrand, Daniel El Fassi, Mikael Frederiksen, Lasse Kjær, Thomas Kielsgaard Kristensen, Torben A Kruse, Torben Mourits-Andersen, Peter Møller, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Vibe Skov, Jesper Stentoft, Jørn Starklint, Karin de Stricker, Mads Thomassen, Thomas Stauffer LarsenHans Carl Hasselbalch

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Abstract

BackgroundRecombinant Interferon Alpha-2a (r-IFNα) is a potent immunomodulating agent, which has been used off-label for the treatment of polycythemia vera (PV) for more than three decades and has been demonstrated to induce high rates of clinical, hematological and molecular responses. Only few studies have compared efficacy and safety of r-IFNα vs. hydroxyurea (HU), which is considered first line therapy for PV patients gt; 60 years in most parts of the world. However, recent studies have provided encouraging results for the treatment of PV with r-IFNα compared to HU irrespective of age (R. Hoffmann 2016; H. Gisslinger 2018).AimsTo examine the difference in efficacy and safety of low-dose r-IFNα in PV patients

Originalsprog	Engelsk
Tidsskrift	Blood
Vol/bind	132
Udgave nummer	Suppl 1
Sider (fra-til)	580
Antal sider	1
ISSN	0006-4971
DOI	https://doi.org/10.1182/blood-2018-99-111255
Status	Udgivet - 2018
Begivenhed	60th ASH Annual Meeting & Exposition - San Diego, USA Varighed: 1 dec. 2018 → 4 dec. 2018 Konferencens nummer: 60

Konference

Konference	60th ASH Annual Meeting & Exposition
Nummer	60
Land/Område	USA
By	San Diego
Periode	01/12/2018 → 04/12/2018

Adgang til dokumentet

10.1182/blood-2018-99-111255

http://www.bloodjournal.org/content/132/Suppl_1/580

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Citationsformater

Knudsen, T. A., Hansen, D. L., Ocias, L. F., Bjerrum, O. W., Brabrand, M., El Fassi, D., Frederiksen, M., Kjær, L., Kristensen, T. K., Kruse, T. A., Mourits-Andersen, T., Møller, P., Overgaard, U. M., Severinsen, M. T., Skov, V., Stentoft, J., Starklint, J., de Stricker, K., Thomassen, M., ... Hasselbalch, H. C. (2018). Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial. Blood, 132(Suppl 1), 580. https://doi.org/10.1182/blood-2018-99-111255

@article{13bfd8af9f05436ba59513a9bfc2d214,

title = "Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial",

abstract = "BackgroundRecombinant Interferon Alpha-2a (r-IFNα) is a potent immunomodulating agent, which has been used off-label for the treatment of polycythemia vera (PV) for more than three decades and has been demonstrated to induce high rates of clinical, hematological and molecular responses. Only few studies have compared efficacy and safety of r-IFNα vs. hydroxyurea (HU), which is considered first line therapy for PV patients gt; 60 years in most parts of the world. However, recent studies have provided encouraging results for the treatment of PV with r-IFNα compared to HU irrespective of age (R. Hoffmann 2016; H. Gisslinger 2018).AimsTo examine the difference in efficacy and safety of low-dose r-IFNα in PV patients ",

author = "Knudsen, {Trine Alma} and Hansen, {Dennis Lund} and Ocias, {Lukas Frans} and Bjerrum, {Ole Weis} and Mette Brabrand and {El Fassi}, Daniel and Mikael Frederiksen and Lasse Kj{\ae}r and Kristensen, {Thomas Kielsgaard} and Kruse, {Torben A} and Torben Mourits-Andersen and Peter M{\o}ller and Overgaard, {Ulrik Malthe} and Severinsen, {Marianne Tang} and Vibe Skov and Jesper Stentoft and J{\o}rn Starklint and {de Stricker}, Karin and Mads Thomassen and Larsen, {Thomas Stauffer} and Hasselbalch, {Hans Carl}",

year = "2018",

doi = "10.1182/blood-2018-99-111255",

language = "English",

volume = "132",

pages = "580",

journal = "Blood",

issn = "0006-4971",

publisher = "AMER SOC HEMATOLOGY",

number = "Suppl 1",

note = "60th ASH Annual Meeting & Exposition ; Conference date: 01-12-2018 Through 04-12-2018",

}

Knudsen, TA, Hansen, DL, Ocias, LF, Bjerrum, OW, Brabrand, M, El Fassi, D, Frederiksen, M, Kjær, L, Kristensen, TK, Kruse, TA, Mourits-Andersen, T, Møller, P, Overgaard, UM, Severinsen, MT, Skov, V, Stentoft, J, Starklint, J, de Stricker, K, Thomassen, M, Larsen, TS & Hasselbalch, HC 2018, 'Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial', Blood, bind 132, nr. Suppl 1, s. 580. https://doi.org/10.1182/blood-2018-99-111255

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial. / Knudsen, Trine Alma; Hansen, Dennis Lund; Ocias, Lukas Frans et al.
I: Blood, Bind 132, Nr. Suppl 1, 2018, s. 580.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

TY - ABST

T1 - Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera

T2 - 60th ASH Annual Meeting & Exposition

AU - Knudsen, Trine Alma

AU - Hansen, Dennis Lund

AU - Ocias, Lukas Frans

AU - Bjerrum, Ole Weis

AU - Brabrand, Mette

AU - El Fassi, Daniel

AU - Frederiksen, Mikael

AU - Kjær, Lasse

AU - Kristensen, Thomas Kielsgaard

AU - Kruse, Torben A

AU - Mourits-Andersen, Torben

AU - Møller, Peter

AU - Overgaard, Ulrik Malthe

AU - Severinsen, Marianne Tang

AU - Skov, Vibe

AU - Stentoft, Jesper

AU - Starklint, Jørn

AU - de Stricker, Karin

AU - Thomassen, Mads

AU - Larsen, Thomas Stauffer

AU - Hasselbalch, Hans Carl

N1 - Conference code: 60

PY - 2018

Y1 - 2018

N2 - BackgroundRecombinant Interferon Alpha-2a (r-IFNα) is a potent immunomodulating agent, which has been used off-label for the treatment of polycythemia vera (PV) for more than three decades and has been demonstrated to induce high rates of clinical, hematological and molecular responses. Only few studies have compared efficacy and safety of r-IFNα vs. hydroxyurea (HU), which is considered first line therapy for PV patients gt; 60 years in most parts of the world. However, recent studies have provided encouraging results for the treatment of PV with r-IFNα compared to HU irrespective of age (R. Hoffmann 2016; H. Gisslinger 2018).AimsTo examine the difference in efficacy and safety of low-dose r-IFNα in PV patients

AB - BackgroundRecombinant Interferon Alpha-2a (r-IFNα) is a potent immunomodulating agent, which has been used off-label for the treatment of polycythemia vera (PV) for more than three decades and has been demonstrated to induce high rates of clinical, hematological and molecular responses. Only few studies have compared efficacy and safety of r-IFNα vs. hydroxyurea (HU), which is considered first line therapy for PV patients gt; 60 years in most parts of the world. However, recent studies have provided encouraging results for the treatment of PV with r-IFNα compared to HU irrespective of age (R. Hoffmann 2016; H. Gisslinger 2018).AimsTo examine the difference in efficacy and safety of low-dose r-IFNα in PV patients

U2 - 10.1182/blood-2018-99-111255

DO - 10.1182/blood-2018-99-111255

M3 - Conference abstract in journal

SN - 0006-4971

VL - 132

SP - 580

JO - Blood

JF - Blood

IS - Suppl 1

Y2 - 1 December 2018 through 4 December 2018

ER -